Unavailable
Unavailable
Save time and jump to the most important pieces.
Beijing, April 22, 2025 (GLOBE NEWSWIRE) -- To the Shareholders of Sinovac Biotech Ltd. and Other Stakeholders: The management of Sinovac Biotech Ltd. (NASDAQ:SVA, "SINOVAC" or the "Company")) recently received notice of its external auditor's decision to resign from its engagement for the Company's year-end audit for the fiscal year 2024. According to the resignation letter, the auditor's decision was prompted by an announcement the Company's current Board made on April 1, 2025, stating that "the current members of the Board are assessing certain corporate actions taken by the former board of directors of the Company after they ceded office." The auditor expressed concern that such a
BOSTON, April 10, 2025 /PRNewswire/ -- Sinovac Biotech Ltd. (NASDAQ:SVA) shareholder Heng Ren Partners, LLC sent a letter on April 8, 2025, to Sinovac's Board calling on the Board to disclose the record and payment dates of the special cash dividend announced on April 1, 2025. More than a week after the dividend announcement, these simple and essential details oddly remain undisclosed. Heng Ren previously sent the Board a letter on March 19, and received no response. The April 8 letter urges Sinovac to pay an additional dividend of $41 per share, which would pay shareholders a total of $96 per share and leave Sinovac with more than $1.3 billion net cash on hand – an amount more than suffi
Sinovac Biotech Ltd. (NASDAQ:SVA) ("SINOVAC" or the "Company"), a leading provider of biopharmaceutical products in China, today announced that the Company's board of directors (the "Board") has decided to declare a special cash dividend of US$55.00 per common share (the "Dividend"). The Board expects to fund the Dividend from available cash resources of the Company and its subsidiaries, including prior distributions from Sinovac Life Sciences Co., Ltd. and other operating subsidiaries of the Company to Sinovac Biotech (Hong Kong) Limited. The Dividend is intended to provide SINOVAC shareholders with their appropriate share of these prior distributions from the Company's subsidiaries. Going
BOSTON, March 20, 2025 /PRNewswire/ -- Sinovac Biotech Ltd. (NASDAQ:SVA) ("Sinovac") shareholder Heng Ren Partners, LLC funds ("Heng Ren") today sent an open letter to Sinovac's shareholders outlining the significant and decisive action that Sinovac's Board of Directors must take to create liquidity and release cash to shareholders. Specifically, Heng Ren demands that Sinovac's Board of Directors announce a distribution of $8.9 billion in cash to its shareholders and cause the resumption of trading of the Company's shares. The full text of the letter follows: March 20, 2025 Dear Fellow Sinovac Shareholders: Like you, we are shareholders in Sinovac Biotech Ltd. ("Sinovac" or the "Company").
Follows Announcement by Sinovac Management Team That External Auditor Resigned Due to Unreliability of Current Board Vivo Capital ("Vivo" or the "Firm"), a leading global investment firm focused exclusively on healthcare and life sciences, today announced multiple legal proceedings to challenge the irresponsible actions taken by the current Board of Directors of Sinovac Biotech Ltd. (NASDAQ:SVA) ("Sinovac" or the "Company") under the control of the activist investor 1Globe Capital LLC ("1Globe") and its allies. In January 2025, the Judicial Committee of the Privy Council in London, England retroactively replaced four members of Sinovac's Board of Directors with individuals nominated by 1G
Beijing, April 22, 2025 (GLOBE NEWSWIRE) -- To the Shareholders of Sinovac Biotech Ltd. and Other Stakeholders: The management of Sinovac Biotech Ltd. (NASDAQ:SVA, "SINOVAC" or the "Company")) recently received notice of its external auditor's decision to resign from its engagement for the Company's year-end audit for the fiscal year 2024. According to the resignation letter, the auditor's decision was prompted by an announcement the Company's current Board made on April 1, 2025, stating that "the current members of the Board are assessing certain corporate actions taken by the former board of directors of the Company after they ceded office." The auditor expressed concern that such a
BOSTON, April 10, 2025 /PRNewswire/ -- Sinovac Biotech Ltd. (NASDAQ:SVA) shareholder Heng Ren Partners, LLC sent a letter on April 8, 2025, to Sinovac's Board calling on the Board to disclose the record and payment dates of the special cash dividend announced on April 1, 2025. More than a week after the dividend announcement, these simple and essential details oddly remain undisclosed. Heng Ren previously sent the Board a letter on March 19, and received no response. The April 8 letter urges Sinovac to pay an additional dividend of $41 per share, which would pay shareholders a total of $96 per share and leave Sinovac with more than $1.3 billion net cash on hand – an amount more than suffi
6-K - SINOVAC BIOTECH LTD (0001084201) (Filer)
6-K - SINOVAC BIOTECH LTD (0001084201) (Filer)
6-K - SINOVAC BIOTECH LTD (0001084201) (Filer)
SC 13D/A - SINOVAC BIOTECH LTD (0001084201) (Subject)
SC 13D/A - SINOVAC BIOTECH LTD (0001084201) (Subject)
SC 13G/A - SINOVAC BIOTECH LTD (0001084201) (Subject)